TMPRSS4通过促进HB-EGF表达及蛋白水解切割驱动肝细胞癌血管生成
该研究探讨HB-EGF在肝细胞癌中的调控机制,发现TMPRSS4通过EGFR/Akt/mTOR/HIF-1α通路增加HB-EGF前体的转录和翻译水平,并通过上调MMP9促进其蛋白水解切割,从而促进血管生成和HCC进展。临床样本中HB-EGF水平与TMPRSS4表达及微血管密度正相关,并可作为总生存和无复发生存的预后因素。HB-EGF抑制剂CRM197单用或联合索拉非尼可显著抑制血管生成和HCC进展。
要点
- TMPRSS4通过增加HB-EGF表达及促进其切割驱动HCC血管生成
- HB-EGF水平与TMPRSS4表达及微血管密度正相关,为预后因素
- HB-EGF抑制剂CRM197联合索拉非尼可抑制HCC进展
核心结论
- HB-EGF受TMPRSS4调控,促进HCC增殖、侵袭和血管生成。
- HB-EGF抑制剂CRM197联合索拉非尼可能用于HCC个体化治疗。
研究设计与样本
- 基础与临床样本结合的机制研究,包含血清和HCC组织样本分析。
主要发现
- TMPRSS4增加HB-EGF前体的转录和翻译水平。
- TMPRSS4通过EGFR/Akt/mTOR/HIF-1α通路上调MMP9促进HB-EGF蛋白水解切割。
- HB-EGF通过EGFR/PI3K/Akt通路促进HCC增殖和侵袭。
- 临床样本中HB-EGF水平与TMPRSS4表达及微血管密度正相关。
- HB-EGF被鉴定为总生存和无复发生存的预后因素。
关键数值与推荐
- HB-EGF抑制剂CRM197单用或联合索拉非尼可显著抑制血管生成和HCC进展。
临床怎么用
- HB-EGF可作为HCC潜在治疗靶点。
- CRM197联合索拉非尼可能用于HCC个体化治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Heparin-binding epidermal growth factor (HB-EGF), a member of the epidermal growth factor family, plays a pivotal role in the progression of several malignancies, but its role and regulatory mechanisms in hepatocellular carcinoma (HCC) remain obscure. Here, we report that transmembrane protease serine 4 (TMPRSS4) significantly enhanced the expression and proteolytic cleavage of HB-EGF to promote angiogenesis and HCC progression. APPROACH AND RESULTS: A mechanistic analysis revealed that TMPRSS4 not only increased the transcriptional and translational levels of HB-EGF precursor, but also promoted its proteolytic cleavage by enhancing matrix metallopeptidase 9 expression through the EGF receptor/Akt/mammalian target of rapamycin/ hypoxia-inducible factor 1 α signaling pathway. In addition, HB-EGF promoted HCC proliferation and invasion by the EGF receptor/phosphoinositide 3-kinase/Akt signaling pathway. The level of HB-EGF in clinical samples of serum or HCC tissues from patients with HCC was positively correlated with the expression of TMPRSS4 and the microvessel density, and was identified as a prognostic factor for overall survival and recurrence-free survival, which suggests that HB-EGF can serve as a potential therapeutic target for HCC. More importantly, we provide a demonstration that treatment with the HB-EGF inhibitor cross-reacting material 197 alone or in combination with sorafenib can significantly suppress angiogenesis and HCC progression. CONCLUSIONS: HB-EGF can be regulated by TMPRSS4 to promote HCC proliferation, invasion, and angiogenesis, and the combination of the HB-EGF inhibitor cross-reacting material 197 with sorafenib might be used for individualized treatment of HCC.
引用
- Dong ZR, Sun D, Yang YF, et al. TMPRSS4 Drives Angiogenesis in Hepatocellular Carcinoma by Promoting HB-EGF Expression and Proteolytic Cleavage. Hepatology. 2020. PMID: 31867749. doi:10.1002/hep.31076
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。